STORMAGIC
11.6.2024 13:01:30 CEST | Business Wire | Press release
StorMagic®, solving the world’s edge data problems, today announced SvHCI, which combines a hypervisor and virtual networking with the provider’s proven virtual storage technology used by thousands of customers around the world. This full-stack HCI (hyperconverged infrastructure) solution is purpose-built for edge and small to medium-sized business (SMB) environments and includes StorMagic’s in-house 24x7x365 customer support.
According to the 2024 Gartner® Market Guide for Full-Stack Hyperconverged Infrastructure Software, “the 30% of the non-market leading full-stack HCI installed base that exists in 2024 will increase to 60% by 2029.”* StorMagic believes that this is validating the significant and growing appetite for this type of storage and compute architecture in the market in the wake of the significant market churn witnessed this year.
StorMagic’s SvSAN® is depended on for 100% uptime by customers who currently use VMware or Microsoft hypervisors and is the foundation of the new full-stack solution. SvHCI is a software solution that installs directly on new or existing servers and includes a KVM-based hypervisor, advanced virtual networking and SvSAN as the storage software layer. Just like SvSAN, StorMagic SvHCI simplifies operations and delivers high availability for edge and SMBs environments with only two servers, while lowering software costs by up to 62% over VMware.**
“StorMagic SvHCI delivers exactly what our customers and partners are telling us they need to run applications reliably at their edge and SMB sites,” said Dan Beer, chief executive officer, StorMagic. “This solution is founded on the same tried and true SvSAN code we have been delivering to customers for more than a decade with over 50,000 installations around the world. With SvHCI, we’re helping end users transition from costly, overengineered, overprovisioned software running on VMware to our purpose-built and dependable solution, saving them up to 62% on software costs alone.”
Pricing and Availability
Generally available later this summer, SvHCI is priced starting at $2,049 for a one-year subscription for a single server and up to 2 TB of storage. StorMagic has also launched today an SvHCI Global Beta Program through which customers and partners can get early access to the software and test on their own servers. To learn more about SvHCI and apply for the Global Beta Program, click here.
* Source: Gartner, Market Guide for Full-Stack Hyperconverged Infrastructure Software, By Jeffrey Hewitt, Philip Dawson, Julia Palmer, Tony Harvey, 8 April 2024.
GARTNER is a registered trademark and service mark of Gartner, Inc. and/or its affiliates in the U.S. and internationally and is used herein with permission. All rights reserved.
**Range of savings is 21% to 62%. Comparisons include SvHCI 1, 3 and 5 year subscription lengths plus maximum storage capacities of 2TB, 6TB, 12TB, 24TB and 48TB. VMware comparisons are for the same subscription length and storage capacity of VMware vSphere Foundation with VMware vSAN and VMware Cloud Foundation with VMware vSAN.
About StorMagic
StorMagic is solving the world’s edge data problems. We help organizations of all types and sizes use, protect and manage their applications and data at and near the edge. Our solutions are easy to implement and maintain, and eliminate downtime to provide value anytime, anywhere. StorMagic’s solutions are simple, reliable and cost-effective, without sacrificing enterprise-class features, for SMBs to Fortune 500 companies with one to thousands of sites.
Join the Conversation
Follow StorMagic on Facebook, Instagram, LinkedIn, and Twitter, and subscribe to our corporate blog and YouTube channel.
StorMagic, SvSAN, SvKMS and SvHCI are trademarks of StorMagic.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240611750413/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CorFlow Therapeutics Announces Successful Completion of Phase 1 and First Patients Enrolled in Phase 2 of the MOCA II Pivotal Trial, Approval to Start the REVITALISE RCT in Europe, and Strengthening of Clinical Leadership30.4.2026 13:00:00 CEST | Press release
Milestones advance clinical progress and path to commercialization CorFlow Therapeutics AG (CorFlow), a clinical-stage company focused on transforming the diagnosis and treatment for heart attack patients, today announced multiple milestones in advancing its clinical program and the strengthening of clinical leadership. Phase 1 of the company’s MOCA II FDA Pivotal Trial was successfully reached after safety and performance goals were met with STEMI heart attack patients who had the proprietary PCoFI diagnostic measurement of microvascular obstruction (MVO) made during a stenting procedure, when compared to the reference standard diagnosis by cardiac MRI in the subsequent days. Phase 1 included 19 patients enrolled across 5 US and 3 European sites. MOCA II follows the FIH MOCA I study and primarily aims to validate the threshold value of the proprietary PCoFI measurement for diagnosing MVO in the setting of primary angioplasty compared to cardiac MRI. This milestone achievement, which w
Agendia to Present New Data Demonstrating the Expanded Clinical Utility of MammaPrint® and BluePrint® at the 2026 ESMO Breast Cancer Annual Congress30.4.2026 13:00:00 CEST | Press release
Poster presentations highlight the prognostic value of MammaPrint + Blueprint in small, node-negative tumors and impact of BMI on recurrence dynamics Agendia®, Inc., a leader in precision oncology for breast cancer, today announced it will present new data at the 2026 European Society for Medical Oncology (ESMO) Annual Congress on Breast Cancer, taking place May 6-8 in Berlin, Germany. The company will present two posters featuring data from the prospective FLEX Study and an independent post hoc analysis of the landmark MINDACT trial that underscore the prognostic value of MammaPrint® + BluePrint® in early-stage breast cancer (EBC). Poster #65P | Thursday, May 7, 13:15 – 14:15 p.m. CEST | Presenter: Elena Shagisultanova Prognostic Performance of MammaPrint in Patients with Small T1a, b, and c Node-Negative Early Breast Cancer A retrospective analysis from the FLEX Study involving 4,349 patients highlights the biological heterogeneity within small, node-negative (T1a, b, and c) tumors –
The Biggest Predictor of Business Growth Is Behavior30.4.2026 09:00:00 CEST | Press release
New IDEO research reveals a gap in the behaviors that most drive growth: long-term vision, rapid experimentation, and team autonomy—with only 10% of leaders saying their company excels at the combination. IDEO, the global design and innovation company, today announced the IDEO Innovation Quotient (IDEO IQ), a new report measuring how workplace behaviors drive business performance across 100 of the world’s largest companies. Those with the highest IDEO IQ scores earned nearly $20 billion in profit last year—50% higher than average and three times more than those ranked at the bottom. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429978890/en/ The IDEO Innovation Quotient (IDEO IQ) is a new report measuring how workplace behaviors drive business performance across 100 of the world’s largest companies. The IDEO IQ surveyed 266 leaders in product and innovation roles at 100 of the world’s largest companies across the Media &
Suzano Sells 12.7 Million Tonnes of Pulp for the First Time in Its History30.4.2026 00:22:00 CEST | Press release
Suzano(B3: SUZB3 | NYSE: SUZ), the world’s largest pulp producer, announces its results for the first quarter of 2026 (1Q26), achieving a new all‑time record in pulp sales. Over the 12‑month period from April 2025 to March 2026, the company sold 12.7 million tonnes of pulp, the highest volume ever recorded in its history. During the same period, Suzano also sold 1.7 million tonnes of paper across the packaging, printing and writing, specialty, and tissue segments. This unprecedented sales level mainly reflects the increase in production capacity following the start‑up of the Ribas do Rio Pardo pulp mill in the state of Mato Grosso do Sul, as well as Suzano’s strong operational efficiency across its production lines and supply chains, serving customers in more than 100 countries worldwide. In the first quarter of 2026, Suzano sold a total of 3.2 million tonnes, comprising 2.8 million tonnes of pulp and 378 thousand tonnes of paper. Net revenue amounted to BRL 11.0 billion, while adjuste
The Estée Lauder Companies Announces Minority Investment in Luxury Clinical Skin Care Brand 111SKIN29.4.2026 22:30:00 CEST | Press release
Surgeon-Founded Brand Anchored by Innovative NAC Y2™ Technology The Estée Lauder Companies Inc. (NYSE:EL) today announced a minority investment in 111SKIN, a luxury clinical skin care brand founded by renowned plastic and reconstructive surgeon Dr. Yannis Alexandrides. Terms of the investment were not disclosed. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429495879/en/ 111SKIN's Reparative Collection Founded in 2012, 111SKIN was originally developed by Dr. Alexandrides to accelerate his patients’ healing time following procedures. At the heart of the brand is its innovative NAC Y2™, a pioneering complex designed to support skin repair and maintain a healthy, radiant and resilient complexion. Building on the foundation of this clinical expertise, 111SKIN has developed a portfolio of more than 30 products, anchored by its Black Diamond and Reparative collections and priced from $50 to $1,000. “Skin care is entering a new
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom